A delayed-start design has been proposed to assess a potential disease-modifying effect in investigational drugs for Alzheimer’s disease that target the underlying disease process. We extended this methodology to recently obtained data from the EXPEDITION3.
EXPEDITION3 was a Phase 3, double-blind study with participants randomized to solanezumab (400 mg) or placebo every 4 weeks for 80 weeks, with an optional extension of active treatment. The delayed-start analysis was designed to determine if a statistically significant treatment difference established during the placebo-controlled period is maintained (at predefined level) during the delayed-start period, which would suggest the active drug has a disease-modifying effect. The delayed-start analysis was assessed across multiple efficacy measures, and includes data from baseline in the placebo-controlled period and up to 9 months in the delayed-start period.
No significant difference was observed between the placebo and solanezumab treatment groups at the end of the placebo-controlled period for the Alzheimer’s Disease Assessment Scale-Cognitive 14-item subscale. A significant treatment difference was observed at the end of the placebo-controlled period for the Alzheimer’s Disease Cooperative Study-Activities of Daily Living instrumental items, an effect also seen at 6 months in the delayed-start period, and the noninferiority criterion was met. No other efficacy measures met these criteria.
Delayed-start statistical methodology was used to understand the longitudinal outcomes in EXPEDITION3 and its extension. The small treatment differences observed at the end of the placebo-controlled phase prevented adequate assessment of any putative disease modifying effect.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Price excludes VAT (USA)
Tax calculation will be finalised during checkout.
Xiong C, van Belle G, Miller JP, Morris JC. Designing clinical trials to test disease-modifying agents: application to the treatment trials of Alzheimer’s disease. Clin Trials. 2011 Feb;8(1):15–26.
Zhang RY, Leon AC, Chuang-Stein C, Romano SJ. A new proposal for randomized start design to investigate disease-modifying therapies for Alzheimer disease. Clin Trials. 2011 Feb;8(1):5–14.
Cummings J, Gould H, Zhong K. Advances in designs for Alzheimer’s disease clinical trials. Am J Neurodegener Dis. 2012;1(3):205–16.
McGhee DJ, Ritchie CW, Zajicek JP, Counsell CE. A review of clinical trial designs used to detect a disease-modifying effect of drug therapy in Alzheimer’s disease and Parkinson’s disease. BMC Neurol. 2016;16:92. doi: 10.1186/s12883-016-0606-3.
Leber P. Slowing the progression of Alzheimer Disease: Methodologic issues. Alzheimer Dis Assoc Disord. 1997;11(Suppl 5):S10–S21.
Liu-Seifert H, Andersen SW, Lipkovich I, Holdridge KC, Siemers E. A novel approach to delayed-start analyses for demonstrating disease-modifying effects in Alzheimer’s disease. PLoS One. 2015b;10(3):e0119632.
Liu-Seifert H, Siemers E, Holdridge KC, et al. Delayed-start analysis: Mild Alzheimer’s disease patients in solanezumab trials, 3.5 years. Alzheimers Dement (N Y) 2015a;1(2):111–121.
FDA Guidance: Guidance for Industry. Alzheimer’s Disease: Developing Drugs for the Treatment of Early Stage Disease. 2013, http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM338287.pdf. Accessed 24 09 2017.
European Medicines Agency Committee for Medicinal Products for Human Use. Draft guideline on the clinical investigation of medicines for the treatment of Alzheimer’s disease and other dementias. Jan 2016 (EMA/CHMP/539931/2014). http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2016/02/WC500200830.pdf. Accessed 6 September 2017.
Doody RS, Thomas RG, Farlow M, et al. Alzheimer’s Disease Cooperative Study Steering Committee.; Solanezumab Study Group. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer’s disease. N Engl J Med. 2014;370(4):311–21.
Siemers E, Sundell K, Carlson C, et al. Phase 3 solanezumab trials: Secondary outcomes in mild Alzheimer’s disease patients. Alzheimers Dement. 2016;12:110–120.
Honig LS, Vellas B, Woodward M, et al. EXPEDITION3: A Phase 3 trial on the efficacy and safety of solanezumab for mild dementia due to Alzheimer’s Disease. N Engl J Med 2017; accepted.
About this article
Cite this article
Liu-Seifert, H., Case, M.G., Andersen, S.W. et al. Delayed-Start Analyses in the Phase 3 Solanezumab EXPEDITION3 Study in Mild Alzheimer’s Disease. J Prev Alzheimers Dis 5, 8–14 (2018). https://doi.org/10.14283/jpad.2018.1